DealsMay 26, 2026, 04:13 PM
Viridian Secures Commercial Manufacturing Deal with WuXi Biologics
AI Summary
Viridian Therapeutics has entered into a Commercial Manufacturing Services Agreement with WuXi Biologics (Hong Kong) Limited. Under the agreement, WuXi Biologics will serve as a non-exclusive supplier for the anticipated long-term commercial supply of veligrotug drug substance and drug product, pending approval. The agreement has an initial five-year term with automatic renewals, features volume-based pricing, and includes provisions for rolling forecasts and termination under specific conditions.
Key Highlights
- Viridian Therapeutics entered a Commercial Manufacturing Services Agreement with WuXi Biologics on May 24, 2026.
- WuXi Biologics will manufacture and supply veligrotug drug substance and drug product for commercial use, if approved.
- WuXi Biologics will be a non-exclusive supplier, allowing Viridian to procure from alternate manufacturers.
- The agreement has an initial term of five years, automatically renewing for successive five-year periods.
- Pricing is volume-based, with the service fee fixed until December 31, 2026, then subject to annual adjustment.
- Viridian will provide rolling monthly forecasts, with a portion considered binding and non-cancellable.
Price Impact
More from VRDN